Multi-targeted kinase inhibition can be combined with cytotoxic chemotherapy backbones to address the molecular heterogeneity of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), diseases characterized by diverse and often co-occurring driver mutations across multiple gene pathways rather than a single actionable lesion. The rationale for such combinations rests on targeting multiple oncogenic pathways simultaneously — rather than restricting use to a molecularly defined subgroup (e.g., FLT3-mutated disease) — reflecting a broader principle in hematologic oncology that agents with multi-kinase activity may have utility independent of a single biomarker-defined patient population.
Multi-targeted kinase inhibition can be combined with cytotoxic chemotherapy backbones to address the molecular heterogeneity of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), disea…